1-(2,6-difluorobenzyl)-3-(2-oxoethyl)-5-(3-methoxyphenyl)-6-methyluracil | 552291-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(2,6-difluorobenzyl)-3-(2-oxoethyl)-5-(3-methoxyphenyl)-6-methyluracil
• 英文别名: 2-[3-[(2,6-Difluorophenyl)methyl]-5-(3-methoxyphenyl)-4-methyl-2,6-dioxopyrimidin-1-yl]acetaldehyde
• CAS: 552291-17-5
• 化学式: C₂₁H₁₈F₂N₂O₄
• 分子量: 400.382
• InChiKey: RXMYYZQOYZNYPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(2-甲基氨基乙基)吡啶 、 1-(2,6-difluorobenzyl)-3-(2-oxoethyl)-5-(3-methoxyphenyl)-6-methyluracil 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 1-(2,6-Difluorobenzyl)-5-(3-methoxyphenyl)-6-methyl-3-[N-methyl-N-(2-pyridylethyl)aminoethyl]uracil
  参考文献：
  名称：

  Identification of 1-Arylmethyl-3- (2-aminoethyl)-5-aryluracil as Novel Gonadotropin-Releasing Hormone Receptor Antagonists

  摘要：

  Based on SAR from hicyclic GnRH antagonists such as 6-aminomethyl-7-arylpyrrolo[1,2-a]pyrimid-4-ones (1) and 2-aryl-3-aminomethylimidazolo[1,2-a]pyrimid-5-ones (2a,b), a series of novel uracil compounds (4) were derived as the GnRH antagonists. Their syntheses and initial SAR are discussed herein. This is the first time that monocycle-based GnRH receptor antagonists are reported.

  DOI：

  10.1021/jm034041s
• 作为产物：
  描述：

  [3-(2,6-Difluoro-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-acetaldehyde 在 四(三苯基膦)钯 、 溴 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 15.0h， 生成 1-(2,6-difluorobenzyl)-3-(2-oxoethyl)-5-(3-methoxyphenyl)-6-methyluracil
  参考文献：
  名称：

  Identification of 1-Arylmethyl-3- (2-aminoethyl)-5-aryluracil as Novel Gonadotropin-Releasing Hormone Receptor Antagonists

  摘要：

  Based on SAR from hicyclic GnRH antagonists such as 6-aminomethyl-7-arylpyrrolo[1,2-a]pyrimid-4-ones (1) and 2-aryl-3-aminomethylimidazolo[1,2-a]pyrimid-5-ones (2a,b), a series of novel uracil compounds (4) were derived as the GnRH antagonists. Their syntheses and initial SAR are discussed herein. This is the first time that monocycle-based GnRH receptor antagonists are reported.

  DOI：

  10.1021/jm034041s